Botswana probes deaths of two people who took AstraZeneca shot
FILE PHOTO: This file photo taken on March 11, 2021, shows vials of the AstraZeneca COVID-19 vaccine in Paris. – AstraZeneca said on April 7, 2021, that two studies conducted by British and European regulators “reaffirmed” that the benefits of its vaccine “far outweigh the risks” despite finding a possible link to rare blood clots. “Overall, both of these reviews reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks,” the British/Swedish company said in a statement. (Photo by JOEL SAGET / AFP)
GABORONE — Botswana is investigating the deaths of two among thousands of people who had been given doses of AstraZeneca’s COVID-19 vaccine to see if there is any link, the health ministry said.
The southern African country has so far administered about 31,000 doses of the AstraZeneca vaccine, the only vaccine it has started rolling out.
India donated 30,000 doses of the vaccine that were manufactured by the Serum Institute of India (SII), and Botswana bought 33,000 doses that were made in South Korea from the global vaccine distribution scheme COVAX.
The two people who died had taken the shots made in India.
AstraZeneca and the SII did not immediately respond to requests for comment from Reuters. Botswana’s health ministry did not say how the people died.
Millions of doses of the AstraZeneca shot have been safely administered around the world. The European Medicines Agency received reports of 169 cases of the rare brain blood clot by early April, after 34 million doses had been administered, Sabine Straus, chair of the EMA’s safety committee, said.
Most of the cases reported had occurred in women under 60.
The Botswana health ministry said in a statement late on Sunday that the two deaths were of elderly people. It did not elaborate. The AstraZeneca doses were made in India and are being distributed under the brand name COVISHIELD.
“The ministry has referred the matter to the regulator being BOMRA for immediate investigation. It is expected that BOMRA investigation will seek to establish the cause of two deaths as well as whether they are in any way linked to the COVID vaccine which was administered,” the statement read.
It advised the public to remain calm and said people who were recovering from recent severe illness should consider delaying getting the vaccine.
Botswana’s investigation comes after Europe’s drug regulator said it had found a possible link between AstraZeneca’s vaccine and very rare cases of blood clots.
Experts say that, even if a causal link is proved between the vaccine and blood clots, the risks of getting a serious clot are minute compared to the risks from possible COVID-19 infection, which can cause similar clots along with other serious symptoms.
Botswana has recorded around 40,000 coronavirus cases and 630 deaths during the pandemic, few by comparison with many other countries around the world, but its diamond-driven economy was hit hard last year, contracting almost 8%.
AstraZeneca’s shot is the cheapest and most readily available. It does not need to be kept at extremely cold temperatures unlike some other vaccines, making it a mainstay of many vaccination programs in the developing world.
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
